Comparison of a Non-Invasive Central Venous Pressure Device and Physical Examination in Patients With Chronic Kidney Disease
Launched by MESPERE LIFESCIENCES INC. · Nov 17, 2010
Trial Information
Current as of July 21, 2025
Withdrawn
Keywords
ClinConnect Summary
The estimation of central venous pressure (CVP) is part of routine clinical examination. Central venous pressure is the indication of the pressure in the right atrium of the heart and it can be measured by determining the height of the blood column in the internal or external jugular vein. Clinical use of CVP has a wide range of applications including diagnosis of heart failure, pleural effusion, hypervolemia, hypovolemia, and sepsis. The standard clinical method for attaining CVP non-invasively is the physical examination of jugular venous pulse (JVP). The JVP provides a useful estimate of...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or older at the time of enrolment
- • Chronic Kidney Disease patients and healthy volunteers
- • Participants should be able to provide written informed consent
- • Subject is termed eligible as determined by Pre-Screening Phase (as defined in protocol)
- Exclusion Criteria:
- • Unable to identify external jugular vein (EJV)
- • Unable to identify internal jugular vein (IJV)
- • Unable to access right side of subject's neck
- • Allergic to adhesive tape
- • History of central vein stenosis
- • Undergoing photodynamic therapy (PDT)
- • Presence of an arteriovenous fistula
About Mespere Lifesciences Inc.
Mespere Lifesciences Inc. is a pioneering clinical trial sponsor focused on advancing innovative therapeutic solutions in the fields of neurology and pain management. With a commitment to enhancing patient outcomes through rigorous research and development, Mespere leverages cutting-edge technologies and a collaborative approach to bring novel treatments from the laboratory to clinical practice. The company prioritizes ethical standards and regulatory compliance, ensuring that all trials are conducted with the highest level of integrity and scientific rigor. Through its dedication to addressing unmet medical needs, Mespere Lifesciences aims to transform the landscape of healthcare and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamilton, Ontario, Canada
Patients applied
Trial Officials
Azim S Gangji, MD
Principal Investigator
St. Joseph's Healthcare Hamilton
Melissa T Perri, MESc
Study Director
Mespere Lifesciences Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials